Huilgol Nagraj G
Division of Radiation Oncology and Division of Hyperthermic Oncology & Medicine, Dr Balalbhai Nanavati Hospital & MRC, Mumbai, India.
Int J Hyperthermia. 2006 Aug;22(5):391-7. doi: 10.1080/02656730600722685.
Arsenic trioxide [ATO] is a pluripotent drug with potentials to have pro-oxidant, angiogenesis inhibitor, flow inhibitor and radiation sensitizer properties.
The present study is a Phase I trial to assess the safety of ATO in advanced or recurrent head and neck cancer treated with radiation and hyperthermia. Patients received ATO at 10, 20 and 30 mg per week a day prior to hyperthermia.
It was assumed that vascular collapse would be complete by 24 h. Administration of ATO at 20 mg was safe with no toxicity due to ATO. No amplification of toxicities due to radiation or hyperthermia was evident. Patients without prior treatment showed better response. A total of 11 patients were included in this Phase I study.
Patients who received 30 mg of ATO weekly showed non-serious acute toxicities. No further escalation of dose was attempted.
三氧化二砷[ATO]是一种具有多种功能的药物，具有促氧化剂、血管生成抑制剂、血流抑制剂和辐射增敏剂的特性。
本研究为I期试验，旨在评估ATO在接受放疗和热疗的晚期或复发性头颈癌患者中的安全性。患者在热疗前每天接受10、20和30毫克/周的ATO治疗。
假设血管塌陷将在24小时内完成。20毫克的ATO给药是安全的，没有因ATO导致的毒性。没有明显的因放疗或热疗导致的毒性增强。未接受过先前治疗的患者显示出更好的反应。本I期研究共纳入11名患者。
每周接受30毫克ATO治疗的患者出现非严重的急性毒性。未尝试进一步提高剂量。
